Biophytis Completes a EUR Two Million B Round Financing
News Oct 04, 2012
Biophytis has announced that it has raised EUR two million (USD 2.6M) in a B round. Metabrain Research, a spin-off of Merck Serono based in Chilly-Mazarin (south of Paris) joined existing investors Seventure partners and CM-CIC Capital Prive in this round.
This funding will enable Biophytis to continue the development of its pipeline of nutraceuticals and drug candidates through two collaborative projects with Metabrain Research.
The first project, SARCOB, targets the treatment of sarcopenic obesity, in partnership with the Myology Institute and Institute of Cardio-metabolism and Nutrition, both at the University of Pierre and Marie Curie (UPMC), and France’s national agricultural research institute, INRA.
The second, MACULIA, focuses on treating age-related macular degeneration, in collaboration with UPMC’s Institut de la Vision and Iris Pharma, a contract research organization dedicated to ophthalmology.
Biophytis leads these two projects, which are sponsored by the Medicen competitivity cluster in the Paris region and which benefit from grants of EUR 2.3 million from a number of European and French local and national government bodies.
“The arrival of Metabrain Research as a shareholder marks a step change in a partnership that we have pursued for several years in the SARCOB project,” said Stanislas Veillet, CEO and founder of Biophytis.
Veillet continued, “It will reinforce our capacity to develop drug candidates derived from our portfolio of nutraceutical active substances, with the aim of signing co-development contracts with pharmaceutical companies.”
“The worldwide market of nutrition, where food and drugs meet, has already reached EUR 120 billion annual revenues and is growing at ten per cent a year,” said Isabelle de Cremoux, general manager at Seventure partners.
Cremoux continued, “This makes it very attractive to many industry players. Biophytis is a pioneer in this field and this financing will allow it to accelerate its development with a strategy targeting both drugs and nutrition.”
“We believe the strategic partnership between our two companies in both the scientific and marketing fields will allow us to develop a portfolio of innovative projects,” said Valerie Autier, CEO of Metabrain Research. “We will be able to offer full coverage of metabolic diseases through a joint nutraceutical and pharmaceutical approach.”
The French and European organizations that are providing grants to the SARCOB and MACULIA projects are FUI (Fonds Unique Interministeriel, a cross-ministry funding body), the European Regional Development Fund, the Essonne and Seine-Saint-Denis departments, the Ile de France region and the city of Paris.
Natural Treatment Alternative to Formaldehyde Eliminates Germs From Hatching EggsNews
Hatching eggs in large-scale hatcheries are currently treated with formaldehyde to eliminate germs. Researchers have now developed a natural alternative.READ MORE
DataArt Joins Biotechnology Association BIO DeutschlandNews
Global technology consultancy DataArt announced today that it has joined BIO Deutschland, Germany's biotechnology industry association.READ MORE
Advantage of Breastfeeding to Increase Mother-Child BondNews
Researchers have found that the molecule RAGE, on the intestinal epithelium, transports oxytocin into the blood even after neonate gut closure. This finding suggests breastfeeding and oral oxytocin administration is advantageous to increase its concentration in blood and mother-child bond.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018